Oral exposure to low-dose Tris (2-butoxyethyl) phosphate (TBEP) levels equivalent to tolerable daily intake may exacerbate allergic pulmonary inflammation by promoting a skewed T-helper 2 cell response, upregulation of ERα and dysregulation of both MLN and BM microenvironments.